About this Research Topic
The regulatory T cells (Tregs), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Besides, they also limit beneficial responses by suppressing sterilizing immunity and limiting anti-tumour immunity. Tregs have multiple mechanisms at their disposal to mediate their suppressive effects. These can be grouped into four basic “modes of action”: suppression by inhibitory cytokines, suppression by cytolysis, suppression by metabolic disruption and suppression by modulation maturation or function for dendritic-cell (DC) and macrophage.
The therapeutic potential of Treg cells has been demonstrated in various preclinical models of numerous indications such as multiple sclerosis, type 1 diabetes mellitus and graft-versus-host disease. In the last 10 years, a few clinical trials aiming to investigate safety and feasibility of Tregs-based therapy have been completed and published with promising result, while an increasing numbers of trials are still ongoing. As more evidence emerges to validate the enormous therapeutic potential of regulatory T cells, there remains basic scientific and clinical development challenges to implement and commercialize Treg directed therapies.
The scope of this Research Topic is to gather a comprehensive list of articles related on Tregs including the latest developments in Treg research and clinical application. The Research Topic will cover various aspects of Tregs ranging from basic research with metabolism and epigenetics and translational research that explore the use of Tregs to treat autoimmune disease and organ allograft, or anti-Treg strategy against tumor.
We welcome the submission of Original Research Articles, Reviews and Mini-reviews, including but not limited to the following topics:
• Mechanisms of Treg induction, proliferation, differentiation, immune regulation and apoptosis.
• Research advancing our understanding in the complexity of “tissue-Tregs” which regulate local homeostatic processes such as metabolism and tissue repair.
• Crosstalk of Tregs with other immune cells, metabolic and epigenetic factors at both cytoplasmic kinase-mediated and nuclear transcriptional factor-mediated levels
• Basic and translational research on anti-Treg strategies for tumor therapy
• Treg-based therapies to induce immune tolerance in hematopoietic stem cell transplantation, organ transplantation & autoimmunity
• How to empower Treg cells in disease and current approaches aimed to activate Tregs in vivo directly (e.g. IL-2)
• Challenges of manufacturing Tregs or generating antigen-specific Tregs and CAR-Tregs
The therapeutic potential of Treg cells has been demonstrated in various preclinical models of numerous indications such as multiple sclerosis, type 1 diabetes mellitus and graft-versus-host disease. In the last 10 years, a few clinical trials aiming to investigate safety and feasibility of Tregs-based therapy have been completed and published with promising result, while an increasing numbers of trials are still ongoing. As more evidence emerges to validate the enormous therapeutic potential of regulatory T cells, there remains basic scientific and clinical development challenges to implement and commercialize Treg directed therapies.
The scope of this Research Topic is to gather a comprehensive list of articles related on Tregs including the latest developments in Treg research and clinical application. The Research Topic will cover various aspects of Tregs ranging from basic research with metabolism and epigenetics and translational research that explore the use of Tregs to treat autoimmune disease and organ allograft, or anti-Treg strategy against tumor.
We welcome the submission of Original Research Articles, Reviews and Mini-reviews, including but not limited to the following topics:
• Mechanisms of Treg induction, proliferation, differentiation, immune regulation and apoptosis.
• Research advancing our understanding in the complexity of “tissue-Tregs” which regulate local homeostatic processes such as metabolism and tissue repair.
• Crosstalk of Tregs with other immune cells, metabolic and epigenetic factors at both cytoplasmic kinase-mediated and nuclear transcriptional factor-mediated levels
• Basic and translational research on anti-Treg strategies for tumor therapy
• Treg-based therapies to induce immune tolerance in hematopoietic stem cell transplantation, organ transplantation & autoimmunity
• How to empower Treg cells in disease and current approaches aimed to activate Tregs in vivo directly (e.g. IL-2)
• Challenges of manufacturing Tregs or generating antigen-specific Tregs and CAR-Tregs
Keywords: Tregs, Immune Regulation, tolerance, anti-tumor strategy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
